REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.
Mehdi Brahmi, Julien Gautier, Armelle Dufresne, Perrine Marec‐Bérard, Claire Cropet, Séraphine Vizoso, Laurie Bissuel, Thibaud Valentin, Natacha Entz‐Werlé, Emmanuelle Bompas, Maud Toulmonde, Elsa Kalbacher, Florence Duffaud, Nicolas Penel, Olivier Mir, Justine Gantzer, Pascaline Boudou‐Rouquette, Nelly Firmin, Isabelle Laure Ray-Coquard, Jean Yves Blay (2022). REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.tps11585.
